GSK2879552

• Description:

  GSK2879552 an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/ KDM1A), with potential antineoplastic activity[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Histone Demethylase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/GSK2879552.html

• Purity:

  99.90

• Solubility:

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(O)C1=CC=C(CN2CCC(CN[C@H]3[C@H](C4=CC=CC=C4)C3)CC2)C=C1

• Molecular Formula:

  C23H28N2O2

• Molecular Weight:

  364.48

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Huang M, et al. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 2017 Apr 2;398:12-21|[2]Mohammad HP, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28 (1) :57-69.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  KDM1/LSD1

• Citation 01:

  Acta Pharmacol Sin. 2022 Feb;43 (2) :457-469.|Bioorg Chem. 2024 Jul 1:150:107603.|bioRxiv. 2024 Dec 23:2024.12.23.630174.|Cancer Chemother Pharmacol. 2019 Feb;83 (2) :277-287.|Cell Rep. 2022 Dec 6;41 (10) :111770.|Cytokine. 2022 Mar:151:155789.|Eur J Med Chem. 2024 Aug 28:278:116801.|Eur J Pharmacol. 2024 Aug 23:176931.|J Endocrinol. 2019 Sep 1; JOE-19-0188.R1.|Mol Cancer Res. 2022 Feb;20 (2) :217-230.|Mol Carcinog. 2023 Aug;62 (8) :1119-1135.|Mol Cell Biochem. 2025 Oct 15.|Mol Cell. 2023 Dec 7;83 (23) :4370-4385.e9.|Nat Chem Biol. 2025 Feb;21 (2) :227-237.|Nat Commun. 2021 Nov 24;12 (1) :6831.|Nat Commun. 2024 May 21;15 (1) :4327.|Natl Sci Rev. 2023 Feb 14;10 (4) :nwad028.|Clin Exp Med. 2025 Nov 25;26 (1) :33.

• CAS Number:

  [1401966-69-5]